|
| |
GenzymeGenzyme is one of the world’s leading biotechnology companies. Its more than 9,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases.
Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2006 revenues of $3.2 billion. Over the past two decades Genzyme has introduced a number of breakthrough treatments in several areas of medicine, which have provided hope to patients who previously had no viable treatment options. Genzyme products are helping patients in nearly 90 countries.
Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. Genzyme, which has its headquarters in Cambridge, Massachusetts, was selected by FORTUNE as one of the “100 Best Companies to Work for” in the United States in 2006 and 2007.
| Contact Details: |
| 500 Kendall Street |
| Cambridge |
| MA |
| 02142 |
| United States of America |
| Tel: | 617 252 7500 |
| Fax: | 617 252 7600 |
| Email: | |
| WWW: | www.genzyme.com/
|
|
Loading...
|
Recent Publications by Genzyme: |  |
Centromeric alpha-satellite DNA break in reciprocal translocations.
In the process of selecting fluorescence in situ hybridization probes to... | 10th November, 2009
| Genzyme Genetics, Monrovia, CA 91016, USA.
| Cytogenet Genome Res. 2009;125(4):329-33. Epub 2009 Oct 27.
DOI Direct Link |
Selecting an appropriate method for expressing a recombinant protein.
Recombinant proteins are important tools for studying biological... | 7th November, 2009
| Genzyme Corporation, Framingham, Massachusetts, USA.
| Methods Enzymol. 2009;463:131-47.
DOI Direct Link |
Expanding the biopharmaceutical industry's involvement in fighting neglected diseases.
The increasingly recognized need for new products for so-called neglected... | 6th November, 2009
| Genzyme Corporation in Cambridge, Massachusetts, USA.
| Health Aff (Millwood). 2009 Nov-Dec;28(6):1774-7.
DOI Direct Link |
Discovery of novel sphingosine kinase 1 inhibitors.
Sphingosine kinase 1 (SK1) is an important enzyme that regulates the... | 6th October, 2009
| Drug and Biomaterial R&D, Genzyme Corporation, 153 Second Avenue, Waltham,
| Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21. Epub 2009 Sep 10.
DOI Direct Link |
[New approaches to rare diseases knowledge]
Primary Myelofibrosis previously also known as Agnogenic Myeloid... | 3rd October, 2009
| Medical Advisor,
| Med Clin (Barc). 2009 Jul 4;133(5):193-5. Epub 2009 May 28.
DOI Direct Link |
→View more Genzyme research publications. |
Press Releases on Genzyme:
|
 |
| Reportlinker Adds Automated and Rapid Microbiological Tests - A Worldwide Market Review |
18th November, 2009 |
Reportlinker |
NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Automated and Rapid Microbiological Tests - A Worldwide Market Review
|
| Reportlinker Adds Organ and Tissue Transplantation - A World Market Analysis |
17th November, 2009 |
Reportlinker |
NEW YORK, Nov. 17 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Organ and Tissue Transplantation - A World Market Analysis
http://www
|
| Reportlinker Adds Cosmetic Surgery Procedures and Products - A US and European Market Review |
17th November, 2009 |
Reportlinker |
NEW YORK, Nov. 17 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Cosmetic Surgery Procedures and Products - A US and European Market Review
|
| American Heart Association Late-breaking Clinical Trial Report: Risks of Anemia Drug Outweigh Benefits in Cardiovascular Disease Patients With Diabetes and Kidney Disease |
16th November, 2009 |
American Heart Association |
Study highlights:
- Risks of an anemia drug appear to outweigh its benefits among diabetic patients with kidney disease, anemia and a history of cardiovascular disease or stroke.
- This first large,
|
| Fate Therapeutics Closes $30 Million Series B Financing |
16th November, 2009 |
Fate Therapeutics, Inc. |
LA JOLLA, Calif., Nov. 16 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 103 individuals from Genzyme using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 1175 times since April 2007, the link to the organisation's website has been followed 143 times Recent Search Terms used to find this page: medical advisor genzyme | 13 novamber and genzym | Genzyme us patent number | genzyme press release 13 november 2009 | different branches genzyme company around the world | james burns at genzyme | huxley pharmaceuticals | Genzyme | genzyme jim burns | recent patent application and aldehyde dehydrogenase identifies a Population of Human Skeletal | . Search for more companies in Cambridge Search for more companies in MA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Genzyme |
